Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
Richard J CassidyYuan LiuKirtesh PatelJim ZhongConor E SteuerDavid A KoobyMaria C RussellTheresa W GillespieJerome C LandryPublished in: Cancer (2016)
In this series, the elimination of neoadjuvant RT for select patients with stage II and III rectal adenocarcinoma was associated with worse OS and should not be recommended outside of a clinical trial. Cancer 2017;123:783-93. © 2016 American Cancer Society.